Oculocutaneous Albinism
Oculocutaneous albinism (OCA) is a group of autosomal recessive inherited disorders of melanin biosynthesis characterized by a generalized reduction or absence of pigmentation of the hair, skin, and eyes together with a characteristic set of developmental ocular abnormalities. The cutaneous phenotype ranges from a complete lifelong lack of melanin (OCA1A) to milder forms with some pigment accumulation over time (OCA1B, OCA2, OCA3, OCA4). The ocular phenotype is the most consistent feature and includes foveal hypoplasia, congenital nystagmus, iris hypopigmentation and transillumination, reduced retinal pigment epithelium pigmentation, reduced visual acuity, refractive errors, photophobia, and misrouting of the optic nerve fibers at the chiasm with consequent strabismus and reduced stereoscopic vision. Non-syndromic OCA is caused by biallelic variants in genes whose products are required for melanin synthesis within the melanosome: TYR (OCA1), OCA2 (OCA2), TYRP1 (OCA3), SLC45A2/MATP (OCA4), and the rarer SLC24A5 (OCA6), LRMDA (OCA7), and DCT (OCA8) loci, with an OCA5 locus mapped to chromosome 4q24. This entry covers NON-SYNDROMIC OCA and is distinct from syndromic albinism such as Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Griscelli syndrome, and the MITF/Waardenburg-Tietz spectrum, which involve additional systemic features and lysosome-related organelle defects beyond the melanosome.
Ask OpenScientist
Ask a research question about Oculocutaneous Albinism. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Classifications
Inheritance
1Show evidence (1 reference)
Subtypes
9Pathophysiology
3Show evidence (2 references)
Show evidence (2 references)
Show evidence (3 references)
Pathograph
Phenotypes
11Eye 4
Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (1 reference)
Integument 2
Show evidence (1 reference)
Show evidence (1 reference)
Other 5
Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (1 reference)
Genetic Associations
8Show evidence (2 references)
Show evidence (1 reference)
Show evidence (2 references)
Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (1 reference)
Medical Actions
6Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (2 references)
Show evidence (1 reference)
Differential Diagnoses
3Conditions with similar clinical presentations that must be differentiated from Oculocutaneous Albinism:
- Skin and hair pigmentation is largely normal in ocular albinism, whereas OCA has generalized cutaneous and hair hypopigmentation.
- Ocular albinism is most commonly X-linked, whereas non-syndromic OCA is autosomal recessive.
Show evidence (1 reference)
- A bleeding diathesis and, in some subtypes, pulmonary fibrosis distinguish Hermansky-Pudlak syndrome from non-syndromic OCA.
Show evidence (1 reference)
- Immunodeficiency, recurrent infections, and silvery hair distinguish Chediak-Higashi and Griscelli syndromes from non-syndromic OCA.
Show evidence (1 reference)
Source YAML
click to showname: Oculocutaneous Albinism
creation_date: '2026-06-17T00:00:00Z'
category: Mendelian
synonyms:
- OCA
- Albinism, oculocutaneous
- Non-syndromic oculocutaneous albinism
description: >
Oculocutaneous albinism (OCA) is a group of autosomal recessive inherited
disorders of melanin biosynthesis characterized by a generalized reduction or
absence of pigmentation of the hair, skin, and eyes together with a
characteristic set of developmental ocular abnormalities. The cutaneous
phenotype ranges from a complete lifelong lack of melanin (OCA1A) to milder
forms with some pigment accumulation over time (OCA1B, OCA2, OCA3, OCA4). The
ocular phenotype is the most consistent feature and includes foveal
hypoplasia, congenital nystagmus, iris hypopigmentation and transillumination,
reduced retinal pigment epithelium pigmentation, reduced visual acuity,
refractive errors, photophobia, and misrouting of the optic nerve fibers at
the chiasm with consequent strabismus and reduced stereoscopic vision.
Non-syndromic OCA is caused by biallelic variants in genes whose products are
required for melanin synthesis within the melanosome: TYR (OCA1), OCA2 (OCA2),
TYRP1 (OCA3), SLC45A2/MATP (OCA4), and the rarer SLC24A5 (OCA6), LRMDA (OCA7),
and DCT (OCA8) loci, with an OCA5 locus mapped to chromosome 4q24. This entry
covers NON-SYNDROMIC OCA and is distinct from syndromic albinism such as
Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Griscelli syndrome, and
the MITF/Waardenburg-Tietz spectrum, which involve additional systemic
features and lysosome-related organelle defects beyond the melanosome.
disease_term:
preferred_term: oculocutaneous albinism
term:
id: MONDO:0018910
label: oculocutaneous albinism
parents:
- Albinism
- Disorder of melanin biosynthesis
- Inherited pigmentary disorder
classifications:
harrisons_chapter:
- classification_value: GENETICS_ENVIRONMENT_DISEASE
- classification_value: DERMATOLOGY
inheritance:
- name: Autosomal Recessive
inheritance_term:
preferred_term: Autosomal recessive inheritance
term:
id: HP:0000007
label: Autosomal recessive inheritance
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "All four types of OCA are inherited as autosomal recessive disorders."
explanation: Establishes the autosomal recessive inheritance pattern of non-syndromic OCA.
has_subtypes:
- name: OCA1A
display_name: OCA1A (TYR, tyrosinase-negative)
description: >
Caused by biallelic null variants in TYR abolishing tyrosinase activity. The
most severe form, with a complete lifelong lack of melanin in skin, hair, and
eyes (white hair, white skin, blue or translucent irides) and no pigment
accumulation over time.
- name: OCA1B
display_name: OCA1B (TYR, tyrosinase-residual)
description: >
Caused by biallelic TYR variants that leave residual (hypomorphic)
tyrosinase activity. Some melanin accumulates over time so hair and skin can
darken with age. This subtype is the target of investigational nitisinone
therapy, which raises plasma tyrosine to stabilize the residual enzyme.
- name: OCA2
display_name: OCA2 (OCA2/P gene)
description: >
Caused by biallelic variants in OCA2 (formerly the P gene), encoding a
melanosomal membrane protein. The most common form of OCA worldwide and the
predominant form in sub-Saharan African populations; affected individuals
typically accumulate some melanin over time.
- name: OCA3
display_name: OCA3 (TYRP1)
description: >
Caused by biallelic variants in TYRP1 encoding tyrosinase-related protein 1.
Often presents as rufous/brown OCA with reddish-brown skin and hair, most
frequently reported in African populations.
- name: OCA4
display_name: OCA4 (SLC45A2/MATP)
description: >
Caused by biallelic variants in SLC45A2 (formerly MATP), encoding a
melanosomal transporter. Phenotypically overlaps with OCA2 and is relatively
common in Japanese and some European populations.
- name: OCA5
display_name: OCA5 (4q24 locus)
description: >
A locus mapped to chromosome 4q24 in a consanguineous Pakistani family; the
causative gene was not definitively established at the time of mapping.
- name: OCA6
display_name: OCA6 (SLC24A5)
description: >
Caused by biallelic variants in SLC24A5, encoding a potassium-dependent
sodium/calcium exchanger active in the melanosome. A rare subtype reported
across European, African, and Asian ancestries.
- name: OCA7
display_name: OCA7 (LRMDA/C10orf11)
description: >
Caused by biallelic variants in LRMDA (formerly C10orf11), encoding a
leucine-rich repeat protein important for melanocyte differentiation. The
rarest defined OCA subtype, with cases reported from the Faroe Islands,
Lithuania, and the Arabian Peninsula.
- name: OCA8
display_name: OCA8 (DCT)
description: >
Caused by biallelic variants in DCT, encoding dopachrome tautomerase
(tyrosinase-related protein 2), an enzyme of the eumelanin synthesis pathway.
A very rare, recently delineated subtype.
prevalence:
- population: General population (all OCA forms, worldwide)
measure_type: POINT_PREVALENCE
prevalence_class: BAND_1_9_PER_100000
rate_per_100000: 5.882353
percentage: Approximately 1 in 17,000
notes: >-
Pooled prevalence estimate across all forms of OCA, implying a carrier
frequency of roughly 1 in 70. Prevalence varies considerably by population
and is markedly higher in parts of sub-Saharan Africa, where OCA2 is common.
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The prevalence of all forms of albinism varies considerably worldwide and has been estimated at approximately 1/17,000, suggesting that about 1 in 70 people carry a gene for OCA."
explanation: Provides the pooled worldwide prevalence and implied carrier frequency for OCA.
pathophysiology:
- name: Melanin Biosynthesis Deficiency
description: >
Melanin is synthesized by melanocytes (skin, hair follicle) and the retinal
pigment epithelium within specialized organelles called melanosomes. The
rate-limiting enzyme tyrosinase (encoded by TYR) catalyzes the conversion of
tyrosine to DOPA and DOPA to dopaquinone, the committed steps of melanin
synthesis. Biallelic loss-of-function variants in TYR (OCA1) abolish or
reduce tyrosinase activity; variants in OCA2, TYRP1, SLC45A2, SLC24A5, DCT,
and LRMDA disrupt downstream enzymatic, transporter, or melanosomal-ion
functions required for normal eumelanin production. The result is absent or
reduced melanin in melanocytes and the retinal pigment epithelium. OCA1A,
with complete tyrosinase deficiency, produces no melanin throughout life,
whereas hypomorphic and non-TYR forms permit some pigment accumulation.
cell_types:
- preferred_term: melanocyte
term:
id: CL:0000148
label: melanocyte
- preferred_term: retinal pigment epithelial cell
term:
id: CL:0002586
label: retinal pigment epithelial cell
locations:
- preferred_term: pigmented layer of retina
term:
id: UBERON:0001782
label: pigmented layer of retina
biological_processes:
- preferred_term: melanin biosynthetic process
term:
id: GO:0042438
label: melanin biosynthetic process
modifier: DECREASED
downstream:
- target: Cutaneous and Hair Hypopigmentation
description: Reduced melanin in epidermal and follicular melanocytes produces hypopigmented skin and hair.
- target: Ocular Hypopigmentation and Foveal Maldevelopment
description: Reduced melanin in the retinal pigment epithelium and iris drives the ocular phenotype.
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Oculocutaneous albinism (OCA) is a group of inherited disorders of melanin biosynthesis characterized by a generalized reduction in pigmentation of hair, skin and eyes."
explanation: Defines OCA as a disorder of melanin biosynthesis with generalized pigmentary reduction.
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "At least four genes are responsible for the different types of the disease (TYR, OCA2, TYRP1 and MATP)."
explanation: Identifies the major non-syndromic OCA genes (TYR, OCA2, TYRP1, SLC45A2/MATP).
- name: Cutaneous and Hair Hypopigmentation
description: >
Reduced or absent melanin in epidermal and hair-follicle melanocytes
produces variable hypopigmentation of the skin and hair. In OCA1A there is a
complete and lifelong absence of pigment (white hair and skin); in OCA1B,
OCA2, OCA3, and OCA4 some pigment accumulates over time, and OCA3 in
particular can present with reddish-brown (rufous) coloration. Because
melanin acts as a broadband ultraviolet protectant and free-radical
scavenger, its loss leaves the skin vulnerable to UV-induced damage and an
increased risk of skin cancer, especially squamous cell carcinoma in
sun-exposed populations.
cell_types:
- preferred_term: melanocyte
term:
id: CL:0000148
label: melanocyte
biological_processes:
- preferred_term: melanin metabolic process
term:
id: GO:0006582
label: melanin metabolic process
modifier: DECREASED
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The degree of skin and hair hypopigmentation varies with the type of OCA."
explanation: Establishes that cutaneous and hair hypopigmentation varies by OCA subtype.
- reference: PMID:30674731
reference_title: One-year pilot study on the effects of nitisinone on melanin in patients with OCA-1B.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In the skin, melanin acts as a broadband protectant against UV light and has free radical scavenging and antioxidant properties"
explanation: Explains why loss of cutaneous melanin in OCA increases vulnerability to UV-induced skin damage.
- name: Ocular Hypopigmentation and Foveal Maldevelopment
description: >
Melanin in the retinal pigment epithelium is required for normal postnatal
development of the fovea and for correct routing of retinal ganglion cell
axons. Reduced RPE and iris melanin in OCA leads to foveal hypoplasia,
reduced visual acuity, fundus hypopigmentation, and iris transillumination.
Crucially, a melanin defect in the RPE causes abnormal decussation
(misrouting) of retinal ganglion cell axons at the optic chiasm, with an
excess of fibers crossing to the contralateral side; this produces reduced
stereoscopic vision and contributes to strabismus. The precise mechanism by
which an RPE pigment defect disrupts development of the adjacent neural
retina remains incompletely understood, but foveal differentiation continues
for months after birth, offering a potential therapeutic window.
cell_types:
- preferred_term: retinal pigment epithelial cell
term:
id: CL:0002586
label: retinal pigment epithelial cell
locations:
- preferred_term: fovea centralis
term:
id: UBERON:0001786
label: fovea centralis
- preferred_term: optic chiasma
term:
id: UBERON:0000959
label: optic chiasma
biological_processes:
- preferred_term: melanin biosynthetic process
term:
id: GO:0042438
label: melanin biosynthetic process
modifier: DECREASED
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Misrouting of the optic nerves is a characteristic finding, resulting in strabismus and reduced stereoscopic vision."
explanation: Establishes optic-nerve misrouting as a characteristic mechanism producing strabismus and reduced stereopsis.
- reference: PMID:30674731
reference_title: One-year pilot study on the effects of nitisinone on melanin in patients with OCA-1B.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "patients with albinism experience a decrease in best-corrected visual acuity and stereopsis due to developmental eye abnormalities, namely hypoplasia of the fovea"
explanation: Links foveal hypoplasia to reduced visual acuity and stereopsis in albinism.
- reference: PMID:30674731
reference_title: One-year pilot study on the effects of nitisinone on melanin in patients with OCA-1B.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Although foveal differentiation begins around 22 weeks of gestation, it continues for months postnatally, offering a potential therapeutic window"
explanation: Supports the postnatal therapeutic window for pigment-restoring interventions in OCA.
phenotypes:
- category: Integumentary
name: Generalized Hypopigmentation (Albinism)
description: >
Generalized reduction or absence of melanin pigmentation affecting the skin,
hair, and eyes. The degree varies from a complete lifelong lack of pigment
in OCA1A to milder, partially pigmented forms in the other subtypes.
frequency: OBLIGATE
phenotype_term:
preferred_term: Albinism
term:
id: HP:0001022
label: Albinism
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Oculocutaneous albinism (OCA) is a group of inherited disorders of melanin biosynthesis characterized by a generalized reduction in pigmentation of hair, skin and eyes."
explanation: Generalized hypopigmentation is the defining cutaneous feature of OCA.
- category: Integumentary
name: Cutaneous Hypopigmentation
description: >
Reduced melanin in the skin, ranging from completely white skin in OCA1A to
variably pigmented skin in milder subtypes.
phenotype_term:
preferred_term: Hypopigmentation of the skin
term:
id: HP:0001010
label: Hypopigmentation of the skin
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Diagnosis is based on clinical findings of hypopigmentation of the skin and hair, in addition to the characteristic ocular symptoms."
explanation: Cutaneous hypopigmentation is a core diagnostic finding in OCA.
- category: Integumentary
name: Hair Hypopigmentation
description: >
Reduced melanin in the hair, ranging from white hair in OCA1A to yellow,
blond, or reddish-brown hair in milder or non-TYR subtypes, with possible
darkening over time.
phenotype_term:
preferred_term: Hypopigmentation of hair
term:
id: HP:0005599
label: Hypopigmentation of hair
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Diagnosis is based on clinical findings of hypopigmentation of the skin and hair, in addition to the characteristic ocular symptoms."
explanation: Hair hypopigmentation is a core diagnostic finding in OCA.
- category: Ophthalmologic
name: Foveal Hypoplasia
description: >
Underdevelopment of the fovea due to lack of retinal pigment epithelium
melanin during retinal development. A near-universal feature of OCA and a
major contributor to reduced visual acuity.
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Hypoplasia of the fovea
term:
id: HP:0007750
label: Hypoplasia of the fovea
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Clinical manifestations include various degrees of congenital nystagmus, iris hypopigmentation and translucency, reduced pigmentation of the retinal pigment epithelium, foveal hypoplasia, reduced visual acuity usually (20/60 to 20/400) and refractive errors, color vision impairment and prominent photophobia."
explanation: Lists foveal hypoplasia among the cardinal ocular manifestations of OCA.
- category: Ophthalmologic
name: Congenital Nystagmus
description: >
Involuntary rhythmic eye movements present from infancy, resulting from the
lack of stable foveal fixation due to foveal hypoplasia.
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Nystagmus
term:
id: HP:0000639
label: Nystagmus
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Clinical manifestations include various degrees of congenital nystagmus, iris hypopigmentation and translucency, reduced pigmentation of the retinal pigment epithelium, foveal hypoplasia, reduced visual acuity usually (20/60 to 20/400) and refractive errors, color vision impairment and prominent photophobia."
explanation: Congenital nystagmus is a cardinal ocular manifestation of OCA.
- category: Ophthalmologic
name: Iris Transillumination Defect
description: >
Lack of melanin in the iris pigment epithelium causes the iris to transmit
light (iris transillumination), a characteristic ocular sign of albinism
that contributes to photophobia.
phenotype_term:
preferred_term: Iris transillumination defect
term:
id: HP:0012805
label: Iris transillumination defect
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Clinical manifestations include various degrees of congenital nystagmus, iris hypopigmentation and translucency, reduced pigmentation of the retinal pigment epithelium, foveal hypoplasia"
explanation: Iris hypopigmentation and translucency (transillumination) are characteristic ocular features of OCA.
- category: Ophthalmologic
name: Reduced Visual Acuity
description: >
Best-corrected visual acuity is reduced, typically in the 20/60 to 20/400
range, due to foveal hypoplasia and abnormal visual pathway development.
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Reduced visual acuity
term:
id: HP:0007663
label: Reduced visual acuity
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "reduced visual acuity usually (20/60 to 20/400) and refractive errors"
explanation: Quantifies the typical reduced visual acuity range in OCA.
- category: Ophthalmologic
name: Fundus Hypopigmentation
description: >
Reduced pigmentation of the retinal pigment epithelium gives a pale,
hypopigmented fundus on ophthalmoscopy with prominent visibility of the
choroidal vasculature.
phenotype_term:
preferred_term: Fundus hypopigmentation
term:
id: HP:0007894
label: Fundus hypopigmentation
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "reduced pigmentation of the retinal pigment epithelium"
explanation: Reduced RPE pigmentation produces the hypopigmented fundus characteristic of OCA.
- category: Ophthalmologic
name: Photophobia
description: >
Marked light sensitivity resulting from iris and fundus hypopigmentation,
which allows excess light to scatter within the eye.
frequency: FREQUENT
phenotype_term:
preferred_term: Photophobia
term:
id: HP:0000613
label: Photophobia
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "color vision impairment and prominent photophobia"
explanation: Prominent photophobia is a cardinal ocular manifestation of OCA.
- category: Ophthalmologic
name: Strabismus
description: >
Ocular misalignment resulting from misrouting of the optic nerve fibers at
the chiasm and reduced stereoscopic vision.
frequency: FREQUENT
phenotype_term:
preferred_term: Strabismus
term:
id: HP:0000486
label: Strabismus
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Misrouting of the optic nerves is a characteristic finding, resulting in strabismus and reduced stereoscopic vision."
explanation: Strabismus results from optic-nerve misrouting in OCA.
- category: Ophthalmologic
name: Abnormal Optic Chiasm (Misrouting)
description: >
Abnormal decussation of retinal ganglion cell axons at the optic chiasm,
with an excess of temporal retinal fibers crossing to the contralateral
hemisphere. This misrouting is a hallmark of albinism detectable by visual
evoked potentials.
phenotype_term:
preferred_term: Abnormal optic chiasm morphology
term:
id: HP:0025163
label: Abnormal optic chiasm morphology
evidence:
- reference: PMID:30674731
reference_title: One-year pilot study on the effects of nitisinone on melanin in patients with OCA-1B.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "abnormal decussation of retinal ganglion cell axons at the level of the optic chiasm"
explanation: Abnormal optic-chiasm decussation (misrouting) is a hallmark developmental abnormality in albinism.
genetic:
- name: TYR Variants (OCA1)
association: Causative
subtype: OCA1A
gene_term:
preferred_term: TYR
term:
id: hgnc:12442
label: TYR
features: >
Biallelic variants in TYR, encoding tyrosinase, the rate-limiting enzyme of
melanin synthesis. Null variants abolishing enzyme activity cause the severe
tyrosinase-negative OCA1A; hypomorphic variants with residual activity cause
OCA1B. TYR is one of the most prevalent OCA genes, particularly in North
American and European populations.
evidence:
- reference: PMID:30674731
reference_title: One-year pilot study on the effects of nitisinone on melanin in patients with OCA-1B.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "mutations in the tyrosinase (TYR, OCA1) gene and the OCA2 gene (formerly, the P gene) are the most prevalent forms of OCA in North America"
explanation: Confirms TYR (OCA1) as one of the most prevalent OCA genes in North America.
- reference: PMID:21968110
reference_title: Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Mutation of the tyrosinase gene (TYR) causes oculocutaneous albinism, type 1 (OCA1), a condition characterized by reduced skin and eye melanin pigmentation and by vision loss."
explanation: Establishes TYR mutations as the cause of OCA1.
- name: TYR Hypomorphic Variants (OCA1B)
association: Causative
subtype: OCA1B
gene_term:
preferred_term: TYR
term:
id: hgnc:12442
label: TYR
features: >
Biallelic hypomorphic TYR variants that retain residual tyrosinase activity,
permitting some melanin accumulation over time. The temperature-sensitive
tyrosinase phenotype is one such hypomorphic form. OCA1B is the specific
target of investigational nitisinone therapy.
evidence:
- reference: PMID:21968110
reference_title: Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "There are 2 forms of OCA1, OCA-1A and OCA-1B. Individuals with the former lack functional tyrosinase and therefore lack melanin, while individuals with the latter produce some melanin."
explanation: Distinguishes OCA1A (no functional tyrosinase) from OCA1B (residual tyrosinase, some melanin).
- name: OCA2 Variants (OCA2)
association: Causative
subtype: OCA2
gene_term:
preferred_term: OCA2
term:
id: hgnc:8101
label: OCA2
features: >
Biallelic variants in OCA2 (formerly the P gene), encoding a melanosomal
membrane protein. OCA2 is the most common form of albinism worldwide and the
predominant form in sub-Saharan Africa, where a common 2.7-kb deletion is
frequent.
evidence:
- reference: PMID:30674731
reference_title: One-year pilot study on the effects of nitisinone on melanin in patients with OCA-1B.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "mutations in the tyrosinase (TYR, OCA1) gene and the OCA2 gene (formerly, the P gene) are the most prevalent forms of OCA in North America"
explanation: Identifies OCA2 (formerly the P gene) as one of the most prevalent OCA genes.
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "At least four genes are responsible for the different types of the disease (TYR, OCA2, TYRP1 and MATP)."
explanation: Lists OCA2 among the major non-syndromic OCA genes.
- name: TYRP1 Variants (OCA3)
association: Causative
subtype: OCA3
gene_term:
preferred_term: TYRP1
term:
id: hgnc:12450
label: TYRP1
features: >
Biallelic variants in TYRP1, encoding tyrosinase-related protein 1, a
melanogenic enzyme. Causes OCA3 (rufous/brown OCA), reported most frequently
in African populations.
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "At least four genes are responsible for the different types of the disease (TYR, OCA2, TYRP1 and MATP)."
explanation: Lists TYRP1 (OCA3) among the major non-syndromic OCA genes.
- name: SLC45A2 Variants (OCA4)
association: Causative
subtype: OCA4
gene_term:
preferred_term: SLC45A2
term:
id: hgnc:16472
label: SLC45A2
features: >
Biallelic variants in SLC45A2 (formerly MATP), encoding a melanosomal
transporter. Causes OCA4, which phenotypically overlaps with OCA2 and is
relatively frequent in Japanese populations.
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "At least four genes are responsible for the different types of the disease (TYR, OCA2, TYRP1 and MATP)."
explanation: Lists MATP (SLC45A2, OCA4) among the major non-syndromic OCA genes.
- name: SLC24A5 Variants (OCA6)
association: Causative
subtype: OCA6
gene_term:
preferred_term: SLC24A5
term:
id: hgnc:20611
label: SLC24A5
features: >
Biallelic variants in SLC24A5, encoding a potassium-dependent sodium/calcium
exchanger active in the melanosome. A rare cause of OCA (OCA6) reported
across multiple ancestries.
evidence:
- reference: PMID:33960688
reference_title: Genetics of non-syndromic and syndromic oculocutaneous albinism in human and mouse.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In this review, we will focus only in the genetics of skin pigmentation in OCA, both in human and mouse, updating our current knowledge on this subject."
explanation: Comprehensive genetics review covering the expanded set of OCA loci including SLC24A5 (OCA6).
- name: LRMDA Variants (OCA7)
association: Causative
subtype: OCA7
gene_term:
preferred_term: LRMDA
term:
id: hgnc:23405
label: LRMDA
features: >
Biallelic variants in LRMDA (formerly C10orf11), encoding a leucine-rich
repeat protein required for melanocyte differentiation. The rarest defined
OCA subtype (OCA7), with cases reported from the Faroe Islands, Lithuania,
and the Arabian Peninsula.
evidence:
- reference: PMID:33960688
reference_title: Genetics of non-syndromic and syndromic oculocutaneous albinism in human and mouse.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In this review, we will focus only in the genetics of skin pigmentation in OCA, both in human and mouse, updating our current knowledge on this subject."
explanation: Comprehensive genetics review covering the expanded set of OCA loci including LRMDA (OCA7).
- name: DCT Variants (OCA8)
association: Causative
subtype: OCA8
gene_term:
preferred_term: DCT
term:
id: hgnc:2709
label: DCT
features: >
Biallelic variants in DCT, encoding dopachrome tautomerase
(tyrosinase-related protein 2), an enzyme of the eumelanin synthesis
pathway. A very rare, recently delineated OCA subtype (OCA8).
evidence:
- reference: PMID:33960688
reference_title: Genetics of non-syndromic and syndromic oculocutaneous albinism in human and mouse.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In this review, we will focus only in the genetics of skin pigmentation in OCA, both in human and mouse, updating our current knowledge on this subject."
explanation: Comprehensive genetics review covering the expanded set of OCA loci including DCT.
diagnosis:
- name: Clinical Examination and Ophthalmologic Evaluation
description: >
Diagnosis is based on the clinical findings of skin and hair
hypopigmentation together with the characteristic ocular features
(nystagmus, iris transillumination, foveal hypoplasia, reduced visual
acuity, photophobia). Ophthalmologic evaluation documents acuity,
refractive error, fundus pigmentation, and nystagmus.
diagnosis_term:
preferred_term: ophthalmologist evaluation
term:
id: MAXO:0000703
label: ophthalmologist evaluation
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Diagnosis is based on clinical findings of hypopigmentation of the skin and hair, in addition to the characteristic ocular symptoms."
explanation: Establishes the clinical basis of OCA diagnosis.
- name: Molecular Genetic Testing
description: >
Because of clinical overlap between OCA forms, molecular genetic testing is
necessary to establish the gene defect and OCA subtype. Targeted gene panels
or exome sequencing identify biallelic pathogenic variants in TYR, OCA2,
TYRP1, SLC45A2, and the rarer loci, and distinguish non-syndromic OCA from
syndromic albinism.
diagnosis_term:
preferred_term: genetic testing
term:
id: MAXO:0000127
label: genetic testing
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Due to the clinical overlap between the OCA forms, molecular diagnosis is necessary to establish the gene defect and OCA subtype."
explanation: Establishes that molecular testing is required to subtype OCA.
differential_diagnoses:
- name: Ocular albinism
description: >-
Ocular albinism presents with the ocular features of albinism (nystagmus,
foveal hypoplasia, iris transillumination, misrouting) but without obvious
skin and hair hypopigmentation, and is typically X-linked.
distinguishing_features:
- >-
Skin and hair pigmentation is largely normal in ocular albinism, whereas OCA
has generalized cutaneous and hair hypopigmentation.
- >-
Ocular albinism is most commonly X-linked, whereas non-syndromic OCA is
autosomal recessive.
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Differential diagnosis includes ocular albinism, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Griscelli syndrome, and Waardenburg syndrome type II."
explanation: Lists ocular albinism among the differential diagnoses of OCA.
- name: Hermansky-Pudlak syndrome
description: >-
A syndromic form of albinism combining oculocutaneous albinism with a
bleeding diathesis (platelet storage pool defect) and, in some subtypes,
pulmonary fibrosis and granulomatous colitis, due to defective biogenesis of
lysosome-related organelles.
distinguishing_features:
- >-
A bleeding diathesis and, in some subtypes, pulmonary fibrosis distinguish
Hermansky-Pudlak syndrome from non-syndromic OCA.
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Differential diagnosis includes ocular albinism, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Griscelli syndrome, and Waardenburg syndrome type II."
explanation: Lists Hermansky-Pudlak syndrome among the syndromic differential diagnoses of OCA.
- name: Chediak-Higashi and Griscelli syndromes
description: >-
Syndromic albinism disorders combining hypopigmentation with immune
dysfunction (Chediak-Higashi) or neurologic/immune features (Griscelli),
reflecting defects in lysosome-related organelle trafficking.
distinguishing_features:
- >-
Immunodeficiency, recurrent infections, and silvery hair distinguish
Chediak-Higashi and Griscelli syndromes from non-syndromic OCA.
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Differential diagnosis includes ocular albinism, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Griscelli syndrome, and Waardenburg syndrome type II."
explanation: Lists Chediak-Higashi and Griscelli syndromes among the syndromic differential diagnoses of OCA.
treatments:
- name: Photoprotection (Sunscreen and Sun Avoidance)
description: >
Because the absence of cutaneous melanin removes UV protection, broad-spectrum
sunscreens, protective clothing, and sun avoidance are recommended to reduce
UV-induced skin damage and skin cancer risk.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Correction of strabismus and nystagmus is necessary and sunscreens are recommended."
explanation: Sunscreens are recommended as standard photoprotective management in OCA.
- name: Regular Skin Cancer Surveillance
description: >
Regular skin checks are offered for early detection of skin cancer, which
occurs at increased incidence in people with OCA owing to the loss of
protective cutaneous melanin.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Regular skin checks for early detection of skin cancer should be offered."
explanation: Supports routine dermatologic surveillance for skin cancer in OCA.
- name: Refractive Correction and Low Vision Aids
description: >
Glasses (possibly bifocals) and dark or photochromic lenses provide help for
reduced visual acuity and photophobia, and low-vision aids support function
in school and daily life.
treatment_term:
preferred_term: eye examination
term:
id: MAXO:0001155
label: eye examination
target_phenotypes:
- preferred_term: Reduced visual acuity
term:
id: HP:0007663
label: Reduced visual acuity
- preferred_term: Photophobia
term:
id: HP:0000613
label: Photophobia
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Glasses (possibly bifocals) and dark glasses or photocromic lenses may offer sufficient help for reduced visual activity and photophobia."
explanation: Supports refractive correction and tinted lenses for visual acuity and photophobia in OCA.
- name: Strabismus and Nystagmus Management
description: >
Correction of strabismus and management of nystagmus are part of routine
ophthalmologic care, addressing ocular misalignment and the head-posture
consequences of nystagmus.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
target_phenotypes:
- preferred_term: Strabismus
term:
id: HP:0000486
label: Strabismus
- preferred_term: Nystagmus
term:
id: HP:0000639
label: Nystagmus
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Correction of strabismus and nystagmus is necessary and sunscreens are recommended."
explanation: Supports correction of strabismus and nystagmus in OCA management.
- name: Nitisinone (Investigational, OCA1B)
description: >
Oral nitisinone, an FDA-approved inhibitor of tyrosine degradation
(4-hydroxyphenylpyruvate dioxygenase) used for hereditary tyrosinemia type 1,
raises plasma tyrosine and is hypothesized to stabilize residual hypomorphic
tyrosinase in OCA1B. In an open-label pilot of 5 adults with OCA1B, nitisinone
did not increase iris melanin but produced small significant increases in hair
and skin pigmentation. This remains investigational rather than an approved
OCA therapy.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: nitisinone
term:
id: CHEBI:50378
label: nitisinone
therapeutic_modality: SMALL_MOLECULE
target_phenotypes:
- preferred_term: Hypopigmentation of the skin
term:
id: HP:0001010
label: Hypopigmentation of the skin
evidence:
- reference: PMID:30674731
reference_title: One-year pilot study on the effects of nitisinone on melanin in patients with OCA-1B.
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Nitisinone did not result in an increase in iris melanin content but may increase hair and skin pigmentation in patients with OCA-1B."
explanation: >-
Pilot human trial showing nitisinone increased hair and skin (but not iris)
pigmentation in OCA1B; supports an investigational, partial benefit.
- reference: PMID:21968110
reference_title: Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism.
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "High levels of tyrosine improved the stability and enzymatic function of the Tyrc-h protein and also increased overall melanin levels in melanocytes from a human with OCA-1B."
explanation: >-
Provides the mechanistic basis for nitisinone in OCA1B - high tyrosine
stabilizes residual tyrosinase and raises melanin in human OCA-1B
melanocytes.
- name: Genetic Counseling
description: >
Genetic counseling explains autosomal recessive inheritance and recurrence
risk; carrier detection and prenatal diagnosis are possible once the
family's disease-causing variants are identified.
treatment_term:
preferred_term: Genetic Counseling
term:
id: NCIT:C15240
label: Genetic Counseling
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Carrier detection and prenatal diagnosis are possible when the disease causing mutations have been identified in the family."
explanation: Supports genetic counseling with carrier and prenatal testing once familial variants are known.
animal_models:
- species: Mouse
genotype: Tyr c-h/c-h (Tyrc-h hypomorphic; OCA-1B model)
description: >
Mice homozygous for the hypomorphic Tyrc-h allele model OCA-1B. Oral
nitisinone increased fur and iris pigmentation and produced more pigmented
melanosomes, supporting the rationale for tyrosine-mediated stabilization of
residual tyrosinase as a therapeutic strategy in OCA1B.
evidence:
- reference: PMID:21968110
reference_title: Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Only nitisinone-treated Tyrc-h/c-h mice manifested increased pigmentation in their fur and irides and had more pigmented melanosomes."
explanation: Demonstrates that nitisinone increases pigmentation in the OCA-1B mouse model.
- species: Mouse
genotype: Tyr c-2J/c-2J (Tyrc-2J null; OCA-1A model)
description: >
Mice homozygous for the Tyrc-2J null allele model tyrosinase-negative OCA-1A.
Unlike the hypomorphic OCA-1B model, these mice did not respond to
nitisinone, consistent with the absence of functional tyrosinase to
stabilize.
evidence:
- reference: PMID:21968110
reference_title: Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "we tested this hypothesis in mice homozygous for either the Tyrc-2J null allele or the Tyrc-h allele, which model OCA-1A and OCA-1B, respectively."
explanation: Establishes the Tyrc-2J null mouse as an OCA-1A model used to test nitisinone.
datasets: []
references:
- reference: PMID:17980020
title: Oculocutaneous albinism.
findings:
- statement: >-
Grønskov et al. provide the foundational Orphanet review of OCA covering
definition, prevalence, clinical spectrum, genetics, diagnosis,
differential diagnosis, and management.
supporting_text: >-
Oculocutaneous albinism (OCA) is a group of inherited disorders of melanin
biosynthesis characterized by a generalized reduction in pigmentation of
hair, skin and eyes.
evidence:
- reference: PMID:17980020
reference_title: Oculocutaneous albinism.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Oculocutaneous albinism (OCA) is a group of inherited disorders of melanin biosynthesis characterized by a generalized reduction in pigmentation of hair, skin and eyes."
explanation: Anchors the foundational clinical and genetic review used throughout this entry.
- reference: PMID:33960688
title: Genetics of non-syndromic and syndromic oculocutaneous albinism in human and mouse.
findings:
- statement: >-
Fernández et al. review the expanded genetics of non-syndromic and
syndromic OCA, distinguishing melanosome-restricted defects from
lysosome-related organelle defects.
supporting_text: >-
There are non-syndromic and syndromic types of OCA, depending on whether
the gene product affected impairs essentially the function of melanosomes
or, in addition, that of other lysosome-related organelles (LROs).
evidence:
- reference: PMID:33960688
reference_title: Genetics of non-syndromic and syndromic oculocutaneous albinism in human and mouse.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "There are non-syndromic and syndromic types of OCA, depending on whether the gene product affected impairs essentially the function of melanosomes or, in addition, that of other lysosome-related organelles (LROs), respectively."
explanation: Distinguishes non-syndromic OCA (this entry) from syndromic albinism.
References & Deep Research
References
2Show evidence (1 reference)
Show evidence (1 reference)
Deep Research
11. Disease Information
Overview / definition
Oculocutaneous albinism (OCA) comprises inherited disorders characterized by reduced or absent melanin biosynthesis affecting eyes, skin, and hair, with characteristic ocular manifestations (e.g., reduced visual acuity, foveal hypoplasia, nystagmus, iris transillumination) and increased UV-related skin disease risk. (ambrosio2025advancinginsightsinto pages 11-13, thomas2023oculocutaneousalbinismanda pages 1-3, kromberg2023determiningaworldwide pages 1-2)
Key identifiers (available from retrieved evidence)
- MeSH: Albinism, Oculocutaneous D016115 (ClinicalTrials.gov browse terms). (NCT07313618 chunk 2)
- MeSH (broader): Albinism D000417. (NCT01176435 chunk 1)
- ICD-10: E70.3 (Albinism) explicitly referenced in a genomic medicine cohort paper using ICD-10 coding. (fassad2026wholegenomesequencinguncovers pages 5-8)
- OMIM (gene/subtype IDs in GeneReviews excerpt): OCA1/TYR 606933, OCA2 611409, OCA3/TYRP1 115501, OCA6/SLC24A5 609802, OCA7/LRMDA 614537, OCA8/DCT 191275, and ocular albinism OA1/GPR143 300808. (thomas2023oculocutaneousalbinismand pages 7-8)
Not captured in retrieved texts during this run: Orphanet/ORDO ORPHA codes, ICD-11 codes, and MONDO identifiers for OCA. (NCT07313618 chunk 2, NCT00001153 chunk 1, NCT04068961 chunk 1)
Synonyms / alternative names (as used in evidence)
- “Oculocutaneous albinism type 1 (OCA1)” (TYR-related). (NCT07313618 chunk 1)
- “Oculocutaneous albinism type 1B (OCA1B)” (residual tyrosinase activity phenotype; nitisinone trial enrollment definition). (NCT01838655 chunk 1, NCT01838655 chunk 7)
- “Ocular albinism (OA)” (often GPR143-related; X-linked). (chan2023diagnosticyieldof pages 1-2, thomas2023oculocutaneousalbinismand pages 16-18)
Evidence source type
The information summarized here is derived from aggregated disease-level resources (GeneReviews overview; systematic review) and cohort studies/trials rather than EHR-only sources. (kromberg2023determiningaworldwide pages 1-2, thomas2023oculocutaneousalbinismand pages 13-16, chan2023diagnosticyieldof pages 2-4)
2. Etiology
Disease causal factors
Primary cause: germline genetic variants disrupting melanogenesis and/or melanosome function. Canonical OCA results from impaired melanin biosynthesis (e.g., TYR) or altered melanosomal homeostasis/biogenesis (e.g., OCA2, SLC45A2). (ambrosio2025advancinginsightsinto pages 11-13, thomas2023oculocutaneousalbinismand pages 13-16)
Genetic risk factors (causal genes)
GeneReviews lists nonsyndromic OCA genes: TYR, OCA2, TYRP1, SLC45A2, SLC24A5, LRMDA (C10orf11), DCT, inherited autosomal recessive; ocular albinism due to GPR143 is X-linked. (thomas2023oculocutaneousalbinismand pages 13-16, thomas2023oculocutaneousalbinismand pages 16-18)
Recent (2024) developments: oligogenic/common-variant contributions
A 2024 Nature Communications study reported that dual heterozygosity for TYR:c.1205G>A (p.Arg402Gln; rs1126809) and OCA2:c.1327G>A (p.Val443Ile; rs74653330) is associated with increased probability of an albinism diagnosis (OR 12.8; 95% CI 6.0–24.7; p=2.1×10−8), and is associated with altered visual acuity and central retinal thickness (endophenotypes). (green2024thecooccurrenceof pages 1-2, green2024thecooccurrenceof pages 2-3)
Environmental risk factors
OCA itself is genetic, but UV exposure is a major determinant of cutaneous morbidity (sun damage, precancer/cancer), motivating strict photoprotection and surveillance. (thomas2023oculocutaneousalbinismand pages 13-16)
Protective factors / gene-environment interactions
No specific protective genetic variants were identified in the retrieved sources in this run. Clinically, sun avoidance and photoprotection reduce downstream UV-related skin disease risk (gene–environment: congenital hypopigmentation increases UV sensitivity; UV behavior modifies outcomes). (thomas2023oculocutaneousalbinismand pages 13-16)
3. Phenotypes
Core ocular phenotypes (with frequencies where available)
A U.S. pediatric cohort (genetically tested OA/OCA; n=53 tested) reported the following phenotype frequencies: - Nystagmus: 89% (chan2023diagnosticyieldof pages 2-4) - Foveal hypoplasia: 85% (chan2023diagnosticyieldof pages 2-4) - Fundus hypopigmentation: 68% (chan2023diagnosticyieldof pages 2-4) - Iris transillumination defects: 38% (chan2023diagnosticyieldof pages 2-4)
GeneReviews summary series report very high frequency of key ocular signs (useful for diagnosis): iris transillumination defects ~91–100%, fundus hypopigmentation >94%, foveal hypoplasia 94–100%, and chiasmal misrouting 84–100%. (thomas2023oculocutaneousalbinismanda pages 1-3)
Additional quantitative clinical descriptors from GeneReviews include strabismus affecting ~71% overall (up to 100% in OCA1), and visual acuity spanning roughly 20/15 to 20/800 with median ~20/80 (logMAR ~0.60). (thomas2023oculocutaneousalbinismand pages 3-7)
Neurodevelopmental and behavioral phenotype (2023 pediatric cohort)
A 2023 European Journal of Pediatrics cohort (18 children, molecularly confirmed OCA) found: - Global neurodevelopmental impairment in 56%, not evolving into intellectual disability. (galli2023oculocutaneousalbinismthe pages 1-2) - Behavioral screening risks: internalizing problems 33%, externalizing 11%, both 28%; autistic-like features in 67% (none meeting autism criteria in that report). (galli2023oculocutaneousalbinismthe pages 1-2, galli2023oculocutaneousalbinismthe pages 5-6) - Visual acuity correlated with performance IQ and adaptive functioning measures. (galli2023oculocutaneousalbinismthe pages 1-2)
Skin/dermatologic phenotype
OCA is associated with increased risk of UV-related skin disease and skin cancers; melanoma detection can be challenging because melanomas may be amelanotic in albinism, motivating regular dermatologic surveillance. (thomas2023oculocutaneousalbinismand pages 13-16)
Suggested HPO terms (examples)
See ontology mapping artifact below (includes HP terms for foveal hypoplasia, nystagmus, strabismus, photophobia, reduced visual acuity, etc.).
4. Genetic / Molecular Information
Causal genes and inheritance
- Autosomal recessive nonsyndromic OCA: TYR, OCA2, TYRP1, SLC45A2, SLC24A5, LRMDA, DCT. (thomas2023oculocutaneousalbinismand pages 13-16)
- X-linked ocular albinism: GPR143. (thomas2023oculocutaneousalbinismand pages 16-18)
The GeneReviews excerpt provides OMIM subtype identifiers for multiple OCA loci (useful for knowledge base cross-references). (thomas2023oculocutaneousalbinismand pages 7-8)
Pathogenic/likely pathogenic variants and variant architecture (recent genetics)
A 2024 study supports an oligogenic susceptibility model for at least a subset of individuals: the TYR p.Arg402Gln and OCA2 p.Val443Ile combination increases diagnosis probability (OR 12.8). (green2024thecooccurrenceof pages 2-3)
Functional consequences and molecular profiling (iPSC model; 2024)
A 2024 iPSC-derived retinal pigment epithelium (RPE) model of OCA1A supports a mechanism in which mutant tyrosinase is absent or inactive and mature pigmented melanosomes are lacking: - TYR mutant misfolding/ER retention and loss of enzymatic activity are discussed as upstream events. (subramani2024generationandcharacterization pages 1-2) - OCA1A RPE showed no pigmented stage III/IV melanosomes, markedly reduced melanin, and absent TYR protein/activity on Western blot and enzyme assays. (subramani2024generationandcharacterization pages 8-11)
Suggested GO / CL terms
See ontology mapping artifact below for suggested GO processes/components (melanin biosynthesis, melanosome organization; ER protein folding) and cell types (melanocyte; retinal pigment epithelial cell; retinal ganglion cell). (subramani2024generationandcharacterization pages 8-11, thomas2023oculocutaneousalbinismanda pages 1-3)
5. Environmental Information
OCA is not environmentally caused; environmental exposures mainly modify downstream morbidity. The primary modifiable environmental factor is UV exposure, which drives sun damage and skin cancer risk in the context of hypopigmented skin. (thomas2023oculocutaneousalbinismand pages 13-16)
6. Mechanism / Pathophysiology
Core causal chain (gene → cell biology → clinical manifestations)
- Upstream genetic defect in melanogenesis genes (e.g., TYR, OCA2) reduces melanin biosynthesis or disrupts melanosome function. (ambrosio2025advancinginsightsinto pages 11-13, thomas2023oculocutaneousalbinismand pages 13-16)
- Cellular/subcellular dysfunction: In TYR-related OCA1A, tyrosinase can be misfolded/retained and enzymatically inactive, yielding absent melanin and abnormal melanosome maturation; iPSC-RPE evidence supports absence of mature pigmented melanosomes and absent TYR activity/protein. (subramani2024generationandcharacterization pages 1-2, subramani2024generationandcharacterization pages 8-11)
- Tissue-level ocular developmental effects: impaired retinal pigmentation associates with foveal hypoplasia and abnormal optic pathway development/misrouting, which contributes to nystagmus, reduced acuity, and strabismus. (ambrosio2025advancinginsightsinto pages 11-13, thomas2023oculocutaneousalbinismanda pages 1-3)
Pathway-level notes
- TYR is described as initiating melanogenesis by converting L-tyrosine to L-DOPA and downstream intermediates. (ambrosio2025advancinginsightsinto pages 11-13)
- OCA2 can modulate melanosome pH, impacting tyrosinase activity (a mechanistic basis for modifier/interaction effects, consistent with oligogenic susceptibility findings). (green2024thecooccurrenceof pages 2-3)
Suggested GO terms / CL terms
Included in artifact-01. (subramani2024generationandcharacterization pages 8-11, thomas2023oculocutaneousalbinismanda pages 1-3)
7. Anatomical Structures Affected
Organ/system level
- Eye/visual system (retina/fovea; optic chiasm/visual pathways): major morbidity and disability driver. (ambrosio2025advancinginsightsinto pages 11-13, thomas2023oculocutaneousalbinismanda pages 1-3)
- Skin: hypopigmentation and UV susceptibility, including skin cancer surveillance burden. (thomas2023oculocutaneousalbinismand pages 13-16)
Tissue/cell level
- Retinal pigment epithelium (RPE) is a key ocular pigment cell population; patient iPSC-derived RPE demonstrates disease-recapitulating pigmentation defects in TYR-related OCA1A. (subramani2024generationandcharacterization pages 1-2, subramani2024generationandcharacterization pages 8-11)
Suggested UBERON terms
Included in artifact-01. (thomas2023oculocutaneousalbinismanda pages 1-3, thomas2023oculocutaneousalbinismand pages 13-16)
8. Temporal Development
OCA is typically congenital/early onset, with visual impairment present from infancy/childhood. Neurodevelopmental delays in the 2023 pediatric cohort appeared early (56% global impairment) and were reported not to progress to intellectual disability. (galli2023oculocutaneousalbinismthe pages 1-2)
9. Inheritance and Population
Inheritance
- Nonsyndromic OCA (TYR, OCA2, TYRP1, SLC45A2, SLC24A5, LRMDA, DCT): autosomal recessive. (thomas2023oculocutaneousalbinismand pages 13-16)
- Ocular albinism (GPR143): X-linked. (thomas2023oculocutaneousalbinismand pages 16-18)
Epidemiology (systematic review; 2023)
A 2023 systematic review found that OCA prevalence estimates are geographically uneven and often outdated: - Only 26/193 countries (13%) had published OCA prevalence figures; studies were disproportionately from Africa. (kromberg2023determiningaworldwide pages 1-2) - Highest prevalence in population isolates ranged 1 in 22 to 1 in 1300 (mean 1 in 464). (kromberg2023determiningaworldwide pages 1-2) - Mean prevalence across four African countries: 1 in 4264 (range 1 in 1755–1 in 7900). (kromberg2023determiningaworldwide pages 1-2) - European estimates (three countries): mean ~1 in 12,000 (range 1 in 10,000–1 in 15,000), potentially underestimated in fair-skinned populations. (kromberg2023determiningaworldwide pages 1-2, kromberg2023determiningaworldwide pages 3-5)
A key data table from this review is captured as an image (see cited table). (kromberg2023determiningaworldwide media 0f424986)
10. Diagnostics
Clinical diagnostic features
High-frequency ocular signs include iris transillumination, fundus hypopigmentation, foveal hypoplasia, nystagmus, and optic pathway misrouting; VEP can support misrouting diagnosis, and OCT supports foveal hypoplasia grading (correlating with visual acuity). (thomas2023oculocutaneousalbinismanda pages 1-3)
Genetic testing yield and real-world implementation (2023)
In a diverse U.S. pediatric cohort, genetic testing had a high diagnostic yield: - Initial yield 66%, increasing to 70% after VUS reinterpretation; yield higher for OCA (76%) than OA (33%, p=0.007). (chan2023diagnosticyieldof pages 1-2) - Most common solved genes were OCA2 (28%) and TYR (20%); Hermansky–Pudlak syndrome variants were identified in 9%. (chan2023diagnosticyieldof pages 1-2)
These data support real-world practice of using multigene panels/exome approaches with periodic reinterpretation of variants. (chan2023diagnosticyieldof pages 2-4)
Differential diagnosis
Syndromic albinism conditions (e.g., Hermansky–Pudlak, Chediak–Higashi) and other pigment/retinal disorders should be considered when systemic features (bleeding diathesis, immunodeficiency, etc.) are present. (ambrosio2025advancinginsightsinto pages 11-13, chan2023diagnosticyieldof pages 1-2)
11. Outcome / Prognosis
Life expectancy is typically not reduced in nonsyndromic OCA, but morbidity is substantial due to lifelong low vision and preventable skin cancer burden; squamous/basal cell carcinomas can contribute to mortality in high UV environments. (kromberg2023determiningaworldwide pages 1-2, thomas2023oculocutaneousalbinismand pages 13-16)
12. Treatment
Current standard management (supportive; real-world implementation)
GeneReviews emphasizes multidisciplinary supportive care: - Ophthalmology surveillance: annual evaluations in children (<16 years), including refractive correction, strabismus/head posture assessment, and filter glasses. (thomas2023oculocutaneousalbinismand pages 13-16) - Low-vision/education interventions: early intervention programs, individualized education plans (IEP), accommodations (magnifiers, enlarged text, assistive technology). (thomas2023oculocutaneousalbinismand pages 13-16) - Dermatology: yearly total body skin exam is recommended with low biopsy threshold; melanoma can be difficult to detect because it may lack pigment; annual to biennial skin examination is recommended depending on exposure and context. (thomas2023oculocutaneousalbinismand pages 13-16) - Avoidance: prolonged unprotected sun exposure should be avoided. (thomas2023oculocutaneousalbinismand pages 13-16)
Emerging/experimental therapies and trials
Nitisinone (OCA1B): A completed NIH/NEI pilot phase 1/2 study (NCT01838655; ClinicalTrials.gov) tested 2 mg oral nitisinone daily for 12 months in 5 adults with OCA1B; the primary endpoint was change in iris pigmentation on an 8-point iris transillumination scale at 12 months, with visual function and pigmentation secondary outcomes. (NCT01838655 chunk 1)
Levodopa (L-DOPA): A completed randomized, placebo-controlled, double-masked phase 2 trial (NCT01176435) enrolled 45 participants (ages 3–60) and tested oral levodopa/carbidopa dosing vs placebo with binocular BCVA as primary outcome over 20 weeks. (NCT01176435 chunk 1)
Gene therapy (OCA1): A recruiting Early Phase 1 trial (NCT07313618; first posted 2026-01-02) tests JWK010 (AAV vector encoding tyrosinase) via a single suprachoroidal injection (3+3 dose escalation; up to 18 children aged 5–12 with biallelic TYR pathogenic variants). Outcomes include safety, BCVA, fundus pigmentation, OCT, ERG, and VEP/MRI optic pathway measures. (NCT07313618 chunk 1)
Suggested MAXO terms
Included in artifact-01 (genetic counseling, ophthalmologic examination, photoprotection, dermatologic surveillance, gene therapy, nitisinone therapy, levodopa therapy). (thomas2023oculocutaneousalbinismand pages 13-16, NCT01838655 chunk 1)
13. Prevention
Primary prevention of OCA is not currently possible (genetic), but prevention of complications is central: - Tertiary prevention: strict photoprotection, avoidance of unprotected sun exposure, and regular dermatologic surveillance to prevent/early-detect precancerous/cancerous lesions. (thomas2023oculocutaneousalbinismand pages 13-16) - Secondary prevention (functional): early vision services and educational accommodations to mitigate developmental/educational impacts of low vision. (thomas2023oculocutaneousalbinismand pages 13-16, galli2023oculocutaneousalbinismthe pages 1-2)
14. Other Species / Natural Disease
No OMIA/veterinary natural disease resources were retrieved in this run. (gap noted)
15. Model Organisms
A 2024 patient-derived iPSC-RPE “disease-in-a-dish” model provides a human cellular model of TYR-related OCA1A with absent pigmentation, absent TYR protein/activity, and defects in mature melanosomes, supporting mechanistic studies and therapeutic development. (subramani2024generationandcharacterization pages 1-2, subramani2024generationandcharacterization pages 8-11)
Embedded Evidence Artifacts
Evidence map table (genes, phenotypes, epidemiology, trials)
| Item | Details / statistics | Evidence source (year; DOI/URL) | Citation |
|---|---|---|---|
| Disease definition and core features | Oculocutaneous albinism (OCA) is a group of genetic disorders with absent or reduced melanin biosynthesis causing hypopigmentation of the eyes, skin, and hair, with common ocular findings including reduced visual acuity, foveal hypoplasia, nystagmus, iris transillumination defects, and optic pathway misrouting. ClinicalTrials.gov also indexes the condition under MeSH Albinism, Oculocutaneous (D016115). | GeneReviews overview (2023); ClinicalTrials.gov NCT07313618 / NCT01838655; https://clinicaltrials.gov/study/NCT07313618 ; https://clinicaltrials.gov/study/NCT01838655 | (thomas2023oculocutaneousalbinismanda pages 1-3, NCT07313618 chunk 1, NCT01838655 chunk 8) |
| Inheritance pattern: nonsyndromic OCA | Nonsyndromic OCA caused by TYR, OCA2, TYRP1, SLC45A2, SLC24A5, LRMDA/C10orf11, DCT/TYRP2 is inherited in an autosomal recessive manner. | GeneReviews overview (2023) | (thomas2023oculocutaneousalbinismand pages 13-16) |
| Inheritance pattern: ocular albinism | Ocular albinism caused by GPR143 (OA1) is inherited in an X-linked manner. | GeneReviews overview (2023) | (thomas2023oculocutaneousalbinismand pages 13-16, thomas2023oculocutaneousalbinismand pages 16-18) |
| Major causal genes: TYR | TYR causes OCA1; TYR encodes tyrosinase, the rate-limiting enzyme of melanin synthesis. OCA1A reflects complete loss of tyrosinase activity; OCA1B reflects residual activity. | Review / GeneReviews-derived summaries (2023); NPJ Genomic Medicine (2022) doi:10.1038/s41525-021-00275-9 https://doi.org/10.1038/s41525-021-00275-9 | (ambrosio2025advancinginsightsinto pages 11-13, thomas2023oculocutaneousalbinismand pages 13-16) |
| Major causal genes: OCA2 | OCA2 causes OCA2 and is a common cause of OCA; in the 2023 U.S. pediatric cohort it accounted for 28% of solved cases. | Genes (2023) doi:10.3390/genes14010135 https://doi.org/10.3390/genes14010135 | (chan2023diagnosticyieldof pages 1-2) |
| Major causal genes: TYRP1 | TYRP1 causes OCA3; TYRP1 supports tyrosinase stability and melanogenesis. | Review summary (2025) / GeneReviews-derived gene list (2023) https://doi.org/10.3390/jcm14020614 | (ambrosio2025advancinginsightsinto pages 11-13, thomas2023oculocutaneousalbinismand pages 13-16) |
| Major causal genes: SLC45A2 | SLC45A2 causes OCA4; implicated as a melanosomal transporter affecting pigmentation. | Review summary (2025) https://doi.org/10.3390/jcm14020614 ; GeneReviews overview (2023) | (ambrosio2025advancinginsightsinto pages 11-13, thomas2023oculocutaneousalbinismand pages 13-16) |
| Major causal genes: SLC24A5 | SLC24A5 causes OCA6; encodes a K+-dependent Na+/Ca2+ exchanger important for melanosome homeostasis/pigmentation. | Pigment Cell Melanoma Res. (2020) doi:10.1111/pcmr.12879 https://doi.org/10.1111/pcmr.12879 ; GeneReviews overview (2023) | (thomas2023oculocutaneousalbinismand pages 13-16) |
| Major causal genes: LRMDA / C10orf11 | LRMDA (C10orf11) is listed among causal genes for autosomal recessive nonsyndromic OCA. | GeneReviews overview (2023) | (thomas2023oculocutaneousalbinismand pages 13-16) |
| Major causal genes: DCT / TYRP2 | DCT (TYRP2) is listed among causal genes for autosomal recessive nonsyndromic OCA. | GeneReviews overview (2023) | (thomas2023oculocutaneousalbinismand pages 13-16) |
| Major causal gene: GPR143 | GPR143 causes X-linked ocular albinism (OA1). | GeneReviews overview (2023) | (thomas2023oculocutaneousalbinismand pages 13-16, thomas2023oculocutaneousalbinismand pages 16-18) |
| Diagnostic yield of genetic testing | In a diverse U.S. pediatric OA/OCA cohort, initial genetic diagnostic yield was 66% (35/53) and increased to 70% after VUS reinterpretation; yield was higher for OCA (76%) than OA (33%, p=0.007). | Genes (2023) doi:10.3390/genes14010135 https://doi.org/10.3390/genes14010135 | (chan2023diagnosticyieldof pages 2-4, chan2023diagnosticyieldof pages 1-2) |
| Ocular phenotype frequency: nystagmus | In the 2023 pediatric testing cohort, nystagmus occurred in 89% of tested OA/OCA patients. | Genes (2023) doi:10.3390/genes14010135 https://doi.org/10.3390/genes14010135 | (chan2023diagnosticyieldof pages 2-4) |
| Ocular phenotype frequency: foveal hypoplasia | In the 2023 pediatric testing cohort, foveal hypoplasia occurred in 85%. GeneReviews reports foveal hypoplasia in 94–100% across OCA/OA series. | Genes (2023) doi:10.3390/genes14010135 https://doi.org/10.3390/genes14010135 ; GeneReviews overview (2023) | (chan2023diagnosticyieldof pages 2-4, thomas2023oculocutaneousalbinismanda pages 1-3) |
| Ocular phenotype frequency: fundus hypopigmentation | In the 2023 pediatric testing cohort, fundus hypopigmentation occurred in 68%. GeneReviews reports fundus hypopigmentation in >94%. | Genes (2023) doi:10.3390/genes14010135 https://doi.org/10.3390/genes14010135 ; GeneReviews overview (2023) | (chan2023diagnosticyieldof pages 2-4, thomas2023oculocutaneousalbinismanda pages 1-3) |
| Ocular phenotype frequency: iris transillumination defects | In the 2023 pediatric testing cohort, iris transillumination defects occurred in 38%. GeneReviews reports iris TID in ~91–100% in classic series. | Genes (2023) doi:10.3390/genes14010135 https://doi.org/10.3390/genes14010135 ; GeneReviews overview (2023) | (chan2023diagnosticyieldof pages 2-4, thomas2023oculocutaneousalbinismanda pages 1-3) |
| Ocular phenotype frequency: chiasmal misrouting | GeneReviews reports abnormal optic chiasm decussation / visual pathway misrouting in 84–100% of tested individuals. | GeneReviews overview (2023) | (thomas2023oculocutaneousalbinismanda pages 1-3) |
| Other ocular burden | Strabismus affects ~71% overall and up to 100% in OCA1; visual acuity can range from about 20/15 to 20/800 with median around 20/80 in reviewed cohorts. | GeneReviews overview (2023) | (thomas2023oculocutaneousalbinismanda pages 3-7, thomas2023oculocutaneousalbinismand pages 3-7) |
| Epidemiology: global summary | A 2023 systematic review found that only 26/193 countries (13%) had published OCA prevalence figures; most data were outdated and African studies were overrepresented (15/34, 44%). | IOVS (2023) doi:10.1167/iovs.64.10.14 https://doi.org/10.1167/iovs.64.10.14 | (kromberg2023determiningaworldwide pages 1-2) |
| Epidemiology: Africa | Mean prevalence across four African countries was 1 in 4,264 (range 1 in 1,755 to 1 in 7,900). | IOVS (2023) doi:10.1167/iovs.64.10.14 https://doi.org/10.1167/iovs.64.10.14 | (kromberg2023determiningaworldwide pages 1-2) |
| Epidemiology: Europe | Mean prevalence across three European countries was ~1 in 12,000 (range 1 in 10,000 to 1 in 15,000), likely underestimated in fair-skinned populations. | IOVS (2023) doi:10.1167/iovs.64.10.14 https://doi.org/10.1167/iovs.64.10.14 | (kromberg2023determiningaworldwide pages 1-2, kromberg2023determiningaworldwide pages 3-5) |
| Epidemiology: population isolates | Highest rates were reported in population isolates, ranging from 1 in 22 to 1 in 1,300 (mean 1 in 464). | IOVS (2023) doi:10.1167/iovs.64.10.14 https://doi.org/10.1167/iovs.64.10.14 | (kromberg2023determiningaworldwide pages 1-2, kromberg2023determiningaworldwide pages 3-5) |
| Epidemiology: common estimates and subtype differences | Older “global” estimates such as 1 in 17,000 are not generalizable. OCA2 is noted as especially common in southern Africa (~1 in 4,000), whereas OCA1 is relatively more common in European cohorts. | IOVS (2023) doi:10.1167/iovs.64.10.14 https://doi.org/10.1167/iovs.64.10.14 | (kromberg2023determiningaworldwide pages 1-2) |
| Current care / surveillance implementation | Real-world management includes annual ophthalmologic follow-up in children, low-vision/educational support, and annual to biennial skin examinations with strict sun protection; yearly dermatologist review is recommended because amelanotic melanoma can be hard to detect. | GeneReviews overview (2023) | (thomas2023oculocutaneousalbinismand pages 13-16) |
| Trial/intervention: nitisinone | NCT01838655; completed NIH/NEI phase 1/2 pilot in adults with OCA1B; 5 participants; 2 mg oral nitisinone daily for 12 months; primary endpoint was mean change in iris pigmentation on an 8-point transillumination scale at 12 months. | ClinicalTrials.gov NCT01838655; first posted 2013; https://clinicaltrials.gov/study/NCT01838655 | (NCT01838655 chunk 1) |
| Trial/intervention: L-DOPA | NCT01176435; completed phase 2 randomized double-masked placebo-controlled trial; 45 participants, ages 3–60 years; tested oral levodopa/carbidopa at two dose levels vs placebo for 20 weeks with binocular best-corrected visual acuity as primary outcome. | ClinicalTrials.gov NCT01176435; first posted 2010; https://clinicaltrials.gov/study/NCT01176435 | (NCT01176435 chunk 1) |
| Trial/intervention: JWK010 gene therapy | NCT07313618; recruiting early phase 1 trial in China; single suprachoroidal AAV-tyrosinase (JWK010) injection in one eye for children 5–12 years with biallelic TYR pathogenic variants; dose-escalation 3+3 design; estimated enrollment 9–18; primary endpoint is safety, with secondary measures including BCVA, fundus pigmentation, SS-OCT macular structure, ERG, and VEP/MRI visual pathway assessment. | ClinicalTrials.gov NCT07313618; first posted 2026-01-02; https://clinicaltrials.gov/study/NCT07313618 | (NCT07313618 chunk 1) |
Table: This table summarizes core disease concepts, genes, phenotype frequencies, epidemiology, and current/emerging interventions for oculocutaneous albinism using the cited GeneReviews, cohort, systematic review, and ClinicalTrials.gov sources. It is useful as a compact evidence map for a disease knowledge base entry.
Ontology mapping table (HPO/GO/CL/UBERON/MAXO suggestions)
| Domain | Term label | Suggested ontology ID | Supporting evidence summary | Citation |
|---|---|---|---|---|
| Phenotype | Foveal hypoplasia | HP:0000647 | Core ocular feature of OCA; reported in 85% of a U.S. pediatric genetic-testing cohort, and 94-100% in GeneReviews summary series. | (chan2023diagnosticyieldof pages 2-4, thomas2023oculocutaneousalbinismanda pages 1-3) |
| Phenotype | Nystagmus | HP:0000639 | Present in 89% of the U.S. pediatric cohort; 100% in the Italian neurodevelopment cohort of 18 children. | (chan2023diagnosticyieldof pages 2-4, galli2023oculocutaneousalbinismthe pages 4-5) |
| Phenotype | Strabismus | HP:0000486 | Reported in ~71% overall and up to 100% in OCA1 in GeneReviews; 78% in the pediatric neurodevelopment cohort. | (thomas2023oculocutaneousalbinismanda pages 3-7, galli2023oculocutaneousalbinismthe pages 4-5) |
| Phenotype | Photophobia | HP:0000613 | Common visual symptom; present in 44% of the pediatric neurodevelopment cohort. | (galli2023oculocutaneousalbinismthe pages 4-5) |
| Phenotype | Iris transillumination defect | HP:0001088 | Seen in 38% of the U.S. cohort and ~91-100% in classic GeneReviews series; useful diagnostic sign. | (chan2023diagnosticyieldof pages 2-4, thomas2023oculocutaneousalbinismanda pages 1-3) |
| Phenotype | Reduced visual acuity | HP:0007663 | Universal or near-universal ocular burden; GeneReviews reports acuity ranging about 20/15-20/800 with median ~20/80, and the neurodevelopment cohort found reduced acuity in 100%. | (thomas2023oculocutaneousalbinismanda pages 3-7, galli2023oculocutaneousalbinismthe pages 4-5) |
| Phenotype | Fundus hypopigmentation / hypopigmented fundus | HP:0007990 | Fundus hypopigmentation occurred in 68% of the U.S. cohort and >94% in GeneReviews summary data. | (chan2023diagnosticyieldof pages 2-4, thomas2023oculocutaneousalbinismanda pages 1-3) |
| Phenotype | Refractive error | HP:0000545 | Refractive errors are frequent in OCA; hypermetropia and with-the-rule astigmatism are common, and 100% of children in the neurodevelopment cohort had refractive errors. | (thomas2023oculocutaneousalbinismanda pages 3-7, galli2023oculocutaneousalbinismthe pages 4-5) |
| Phenotype | Abnormal head posture | HP:0000456 | Anomalous/abnormal head posture is common in albinism; 89% in the neurodevelopment cohort. | (thomas2023oculocutaneousalbinismanda pages 3-7, galli2023oculocutaneousalbinismthe pages 4-5) |
| Phenotype | Glare sensitivity | HP:0000746 | All 65 participants in a Botswana real-world cohort reported glare sensitivity (100%), supporting its relevance to low-vision management. | (thomas2023oculocutaneousalbinismanda pages 3-7) |
| Phenotype | Skin cancer susceptibility / increased skin cancer risk | HP:0032445 | OCA confers increased UV-related skin disease risk including SCC, BCC, melanoma, and Merkel cell carcinoma; annual to biennial skin examination is recommended. | (thomas2023oculocutaneousalbinismanda pages 3-7, thomas2023oculocutaneousalbinismand pages 13-16) |
| Phenotype | Global developmental delay / neurodevelopmental impairment | HP:0001263 | In a 2023 pediatric cohort, 56% had global neurodevelopmental impairment without progression to intellectual disability. | (galli2023oculocutaneousalbinismthe pages 1-2, galli2023oculocutaneousalbinismthe pages 5-6) |
| Phenotype | Autistic-like features / behavioral abnormality | HP:0000729 | 67% of children in the neurodevelopment cohort showed one or more autistic-like features; internalizing behavioral risk occurred in 33%. | (galli2023oculocutaneousalbinismthe pages 1-2, galli2023oculocutaneousalbinismthe pages 5-6) |
| Mechanism | Melanin biosynthetic process | GO:0042438 | Central upstream defect in OCA; TYR is the rate-limiting enzyme and impaired melanin biosynthesis underlies hypopigmentation and abnormal ocular development. | (ambrosio2025advancinginsightsinto pages 11-13, subramani2024generationandcharacterization pages 1-2) |
| Mechanism | Melanosome organization | GO:0032438 | Multiple OCA genes affect melanosome biogenesis/maturation; OCA1A iPSC-RPE showed absence of mature stage III/IV pigmented melanosomes. | (ambrosio2025advancinginsightsinto pages 11-13, subramani2024generationandcharacterization pages 8-11) |
| Mechanism | Melanosome membrane | GO:0031902 | OCA2 and SLC45A2 act through melanosomal function/pH regulation; disease mechanisms localize to melanosome-associated membrane systems. | (ambrosio2025advancinginsightsinto pages 11-13, green2024thecooccurrenceof pages 2-3) |
| Mechanism | Endoplasmic reticulum retention / protein folding defect | GO:0034976 | OCA1A TYR mutant protein can misfold, be retained in the ER, and lose enzymatic activity; iPSC-RPE showed absent TYR protein/activity. | (subramani2024generationandcharacterization pages 1-2, subramani2024generationandcharacterization pages 8-11) |
| Mechanism | Regulation of melanosomal pH | OCA2 modulates melanosome pH, affecting tyrosinase activity; SLC24A5 and SLC45A2 are also implicated in melanosome homeostasis. | (ambrosio2025advancinginsightsinto pages 11-13, green2024thecooccurrenceof pages 2-3) | |
| Mechanism | Visual pathway misrouting / abnormal optic nerve decussation | Chiasmal misrouting is a hallmark downstream developmental consequence of reduced melanin, reported in 84-100% in GeneReviews. | (thomas2023oculocutaneousalbinismanda pages 1-3) | |
| Cell type | Melanocyte | CL:0000148 | Primary pigment-producing cell type affected in skin/hair hypopigmentation; relevant to UV protection and cutaneous cancer susceptibility. | (ambrosio2025advancinginsightsinto pages 11-13, kromberg2023determiningaworldwide pages 1-2) |
| Cell type | Retinal pigment epithelial cell | CL:0002586 | Key ocular pigment cell type; patient-derived OCA1A iPSC-RPE lacked pigmentation, TYR protein, and mature melanosomes. | (subramani2024generationandcharacterization pages 1-2, subramani2024generationandcharacterization pages 8-11) |
| Cell type | Retinal ganglion cell | CL:0000740 | Relevant to optic pathway development and chiasmal misrouting in albinism. | (ambrosio2025advancinginsightsinto pages 11-13, thomas2023oculocutaneousalbinismanda pages 1-3) |
| Anatomy | Eye | UBERON:0000970 | Primary organ affected with reduced pigmentation, refractive abnormalities, nystagmus, strabismus, and low vision. | (ambrosio2025advancinginsightsinto pages 11-13, galli2023oculocutaneousalbinismthe pages 4-5) |
| Anatomy | Retina | UBERON:0000966 | Retinal hypopigmentation and structural abnormalities are central to disease; OCT often demonstrates foveal hypoplasia. | (ambrosio2025advancinginsightsinto pages 11-13, thomas2023oculocutaneousalbinismanda pages 1-3) |
| Anatomy | Fovea centralis | UBERON:0006612 | Developmentally underformed in OCA; severity correlates with visual acuity. | (thomas2023oculocutaneousalbinismanda pages 3-7, thomas2023oculocutaneousalbinismanda pages 1-3) |
| Anatomy | Optic chiasm | UBERON:0001709 | Site of abnormal decussation / visual pathway misrouting. | (ambrosio2025advancinginsightsinto pages 11-13, thomas2023oculocutaneousalbinismanda pages 1-3) |
| Anatomy | Skin | UBERON:0002097 | Major extraocular site of hypopigmentation and UV-related morbidity. | (kromberg2023determiningaworldwide pages 1-2, thomas2023oculocutaneousalbinismand pages 13-16) |
| Anatomy | Epidermis | UBERON:0001003 | Relevant cutaneous compartment for melanin deficiency and photoprotection interventions. | (kromberg2023determiningaworldwide pages 1-2, thomas2023oculocutaneousalbinismand pages 13-16) |
| Intervention | Genetic counseling | MAXO:0000055 | Recommended for inheritance risk assessment, carrier testing, family planning, and prenatal/preimplantation testing once familial variants are known. | (thomas2023oculocutaneousalbinismand pages 13-16, thomas2023oculocutaneousalbinismand pages 16-18) |
| Intervention | Low vision rehabilitation | GeneReviews recommends low-vision clinic review as needed; educational accommodations, magnifiers, enlarged text, and assistive technology are standard real-world supports. | (thomas2023oculocutaneousalbinismand pages 13-16) | |
| Intervention | Sunscreen / photoprotection | Strict sun protection is standard supportive care; annual to biennial skin examination is recommended because UV-related skin damage risk is increased. | (thomas2023oculocutaneousalbinismand pages 13-16) | |
| Intervention | Dermatologic surveillance | Yearly total-body skin examination by a trained dermatologist is highly recommended; low threshold for biopsy because melanoma may be amelanotic. | (thomas2023oculocutaneousalbinismand pages 13-16) | |
| Intervention | Ophthalmologic examination | Annual ophthalmologic review in children is recommended, including refractive error, strabismus/head posture, and filter-glass needs; OCT/VEP are useful diagnostic adjuncts. | (thomas2023oculocutaneousalbinismand pages 13-16, thomas2023oculocutaneousalbinismanda pages 1-3) | |
| Intervention | Gene therapy | Early-phase interventional development is active: JWK010 (AAV-tyrosinase) is a recruiting dose-escalation OCA1 trial using suprachoroidal injection with safety as the primary endpoint. | (NCT07313618 chunk 1) | |
| Intervention | Nitisinone therapy | Completed NIH pilot trial in adult OCA1B used 2 mg oral nitisinone daily for 12 months to assess iris pigmentation and visual outcomes. | (NCT01838655 chunk 1) | |
| Intervention | Levodopa therapy | Completed randomized placebo-controlled phase 2 trial tested oral levodopa/carbidopa in 45 individuals with albinism over 20 weeks, with binocular BCVA as the primary endpoint. | (NCT01176435 chunk 1) |
Table: This table maps major oculocutaneous albinism phenotypes, mechanisms, anatomical sites, cell types, and management strategies to suggested ontology terms. It is designed as a knowledge-base ready artifact that links clinical and mechanistic evidence to HPO, GO, CL, UBERON, and MAXO concepts with supporting citations.
Key visual evidence (epidemiology table image)
The prevalence-by-continent table from the 2023 systematic review is provided as a cropped figure for direct use in epidemiology extraction workflows. (kromberg2023determiningaworldwide media 0f424986)
Notes on evidence gaps relative to requested template
- MONDO / Orphanet / ICD-11 identifiers: not present in the retrieved evidence during this run; would require direct ontology/registry queries beyond the current tool evidence set. (NCT07313618 chunk 2, NCT04068961 chunk 1)
- PMIDs: Some items (e.g., GeneReviews overview and ClinicalTrials.gov records) are not primarily indexed by PMID; where possible, the GeneReviews reference list indicates related PubMed-indexed trials/papers, but PMIDs were not consistently extractable from the current text chunks. (thomas2023oculocutaneousalbinismand pages 16-18, NCT01838655 chunk 1)
References
-
(ambrosio2025advancinginsightsinto pages 11-13): Lucia Ambrosio, Tatiana Perepelkina, Abdelrahman M. Elhusseiny, Anne B. Fulton, and Jose Efren Gonzalez Monroy. Advancing insights into pediatric macular diseases: a comprehensive review. Journal of Clinical Medicine, 14:614, Jan 2025. URL: https://doi.org/10.3390/jcm14020614, doi:10.3390/jcm14020614. This article has 4 citations.
-
(thomas2023oculocutaneousalbinismanda pages 1-3): MG Thomas, J Zippin, and BP Brooks. Oculocutaneous albinism and ocular albinism overview. Unknown journal, 2023.
-
(kromberg2023determiningaworldwide pages 1-2): Jennifer G. R. Kromberg, Kaitlyn A. Flynn, and Robyn A. Kerr. Determining a worldwide prevalence of oculocutaneous albinism: a systematic review. Investigative Opthalmology & Visual Science, 64:14, Jul 2023. URL: https://doi.org/10.1167/iovs.64.10.14, doi:10.1167/iovs.64.10.14. This article has 61 citations.
-
(NCT07313618 chunk 2): Fang Lu. Safety and Efficacy of a Single Suprachoroidal Injection of JWK010 Gene Therapy in Subjects With Oculocutaneous Albinism Type 1 (OCA1). West China Hospital. 2025. ClinicalTrials.gov Identifier: NCT07313618
-
(NCT01176435 chunk 1): Trial of L-DOPA as a Treatment to Improve Vision in Albinism. University of Minnesota. 2010. ClinicalTrials.gov Identifier: NCT01176435
-
(fassad2026wholegenomesequencinguncovers pages 5-8): Mahmoud R. Fassad, Pradeep C. Vasudevan, Julian Barwell, Gail DE Maconachie, Savita Madhusudhan, David Hunt, Irene Gottlob, Mariya Moosajee, Omar A. Mahroo, Andrew R. Webster, Michel Michaelides, and Mervyn G. Thomas. Whole-genome sequencing uncovers diverse genetic causes and phenotypic signatures in infantile nystagmus and albinism. npj Genomic Medicine, May 2026. URL: https://doi.org/10.1038/s41525-026-00580-1, doi:10.1038/s41525-026-00580-1. This article has 0 citations and is from a peer-reviewed journal.
-
(thomas2023oculocutaneousalbinismand pages 7-8): MG Thomas, J Zippin, and BP Brooks. Oculocutaneous albinism and ocular albinism overview. Unknown journal, 2023.
-
(NCT00001153 chunk 1): Visual Function and Ocular Pigmentation in Albinism. National Eye Institute (NEI). 1976. ClinicalTrials.gov Identifier: NCT00001153
-
(NCT04068961 chunk 1): New Strategies of Genetic Study of Patients With Oculocutaneous Albinism. University Hospital, Bordeaux. 2010. ClinicalTrials.gov Identifier: NCT04068961
-
(NCT07313618 chunk 1): Fang Lu. Safety and Efficacy of a Single Suprachoroidal Injection of JWK010 Gene Therapy in Subjects With Oculocutaneous Albinism Type 1 (OCA1). West China Hospital. 2025. ClinicalTrials.gov Identifier: NCT07313618
-
(NCT01838655 chunk 1): Nitisinone for Type 1B Oculocutaneous Albinism. National Eye Institute (NEI). 2013. ClinicalTrials.gov Identifier: NCT01838655
-
(NCT01838655 chunk 7): Nitisinone for Type 1B Oculocutaneous Albinism. National Eye Institute (NEI). 2013. ClinicalTrials.gov Identifier: NCT01838655
-
(chan2023diagnosticyieldof pages 1-2): Kyle S Chan, Brenda L. Bohnsack, Alexander Ing, Andrew Drackley, Valerie Castelluccio, Kevin X. Zhang, Hantamalala Ralay-Ranaivo, and Jennifer L. Rossen. Diagnostic yield of genetic testing for ocular and oculocutaneous albinism in a diverse united states pediatric population. Genes, 14:135, Jan 2023. URL: https://doi.org/10.3390/genes14010135, doi:10.3390/genes14010135. This article has 13 citations.
-
(thomas2023oculocutaneousalbinismand pages 16-18): MG Thomas, J Zippin, and BP Brooks. Oculocutaneous albinism and ocular albinism overview. Unknown journal, 2023.
-
(thomas2023oculocutaneousalbinismand pages 13-16): MG Thomas, J Zippin, and BP Brooks. Oculocutaneous albinism and ocular albinism overview. Unknown journal, 2023.
-
(chan2023diagnosticyieldof pages 2-4): Kyle S Chan, Brenda L. Bohnsack, Alexander Ing, Andrew Drackley, Valerie Castelluccio, Kevin X. Zhang, Hantamalala Ralay-Ranaivo, and Jennifer L. Rossen. Diagnostic yield of genetic testing for ocular and oculocutaneous albinism in a diverse united states pediatric population. Genes, 14:135, Jan 2023. URL: https://doi.org/10.3390/genes14010135, doi:10.3390/genes14010135. This article has 13 citations.
-
(green2024thecooccurrenceof pages 1-2): David J. Green, Vincent Michaud, Eulalie Lasseaux, Claudio Plaisant, Tomas Fitzgerald, Ewan Birney, Graeme C. Black, Benoît Arveiler, and Panagiotis I. Sergouniotis. The co-occurrence of genetic variants in the tyr and oca2 genes confers susceptibility to albinism. Nature Communications, Sep 2024. URL: https://doi.org/10.1038/s41467-024-52763-y, doi:10.1038/s41467-024-52763-y. This article has 9 citations and is from a highest quality peer-reviewed journal.
-
(green2024thecooccurrenceof pages 2-3): David J. Green, Vincent Michaud, Eulalie Lasseaux, Claudio Plaisant, Tomas Fitzgerald, Ewan Birney, Graeme C. Black, Benoît Arveiler, and Panagiotis I. Sergouniotis. The co-occurrence of genetic variants in the tyr and oca2 genes confers susceptibility to albinism. Nature Communications, Sep 2024. URL: https://doi.org/10.1038/s41467-024-52763-y, doi:10.1038/s41467-024-52763-y. This article has 9 citations and is from a highest quality peer-reviewed journal.
-
(thomas2023oculocutaneousalbinismand pages 3-7): MG Thomas, J Zippin, and BP Brooks. Oculocutaneous albinism and ocular albinism overview. Unknown journal, 2023.
-
(galli2023oculocutaneousalbinismthe pages 1-2): Jessica Galli, Erika Loi, Laura Dusi, Nadia Pasini, Andrea Rossi, Vera Scaglioni, Lucia Mauri, and Elisa Fazzi. Oculocutaneous albinism: the neurological, behavioral, and neuro-ophthalmological perspective. European Journal of Pediatrics, 182:2723-2733, Apr 2023. URL: https://doi.org/10.1007/s00431-023-04938-w, doi:10.1007/s00431-023-04938-w. This article has 14 citations and is from a peer-reviewed journal.
-
(galli2023oculocutaneousalbinismthe pages 5-6): Jessica Galli, Erika Loi, Laura Dusi, Nadia Pasini, Andrea Rossi, Vera Scaglioni, Lucia Mauri, and Elisa Fazzi. Oculocutaneous albinism: the neurological, behavioral, and neuro-ophthalmological perspective. European Journal of Pediatrics, 182:2723-2733, Apr 2023. URL: https://doi.org/10.1007/s00431-023-04938-w, doi:10.1007/s00431-023-04938-w. This article has 14 citations and is from a peer-reviewed journal.
-
(subramani2024generationandcharacterization pages 1-2): Janavi Subramani, Niharika Patlolla, Rajani Battu, Taslimarif Saiyed, and Rajarshi Pal. Generation and characterization of retinal pigment epithelium from patient ipsc line to model oculocutaneous albinism (oca)1a disease. Journal of Biosciences, 49:1-14, Jan 2024. URL: https://doi.org/10.1007/s12038-023-00406-7, doi:10.1007/s12038-023-00406-7. This article has 5 citations and is from a peer-reviewed journal.
-
(subramani2024generationandcharacterization pages 8-11): Janavi Subramani, Niharika Patlolla, Rajani Battu, Taslimarif Saiyed, and Rajarshi Pal. Generation and characterization of retinal pigment epithelium from patient ipsc line to model oculocutaneous albinism (oca)1a disease. Journal of Biosciences, 49:1-14, Jan 2024. URL: https://doi.org/10.1007/s12038-023-00406-7, doi:10.1007/s12038-023-00406-7. This article has 5 citations and is from a peer-reviewed journal.
-
(kromberg2023determiningaworldwide pages 3-5): Jennifer G. R. Kromberg, Kaitlyn A. Flynn, and Robyn A. Kerr. Determining a worldwide prevalence of oculocutaneous albinism: a systematic review. Investigative Opthalmology & Visual Science, 64:14, Jul 2023. URL: https://doi.org/10.1167/iovs.64.10.14, doi:10.1167/iovs.64.10.14. This article has 61 citations.
-
(kromberg2023determiningaworldwide media 0f424986): Jennifer G. R. Kromberg, Kaitlyn A. Flynn, and Robyn A. Kerr. Determining a worldwide prevalence of oculocutaneous albinism: a systematic review. Investigative Opthalmology & Visual Science, 64:14, Jul 2023. URL: https://doi.org/10.1167/iovs.64.10.14, doi:10.1167/iovs.64.10.14. This article has 61 citations.
-
(NCT01838655 chunk 8): Nitisinone for Type 1B Oculocutaneous Albinism. National Eye Institute (NEI). 2013. ClinicalTrials.gov Identifier: NCT01838655
-
(thomas2023oculocutaneousalbinismanda pages 3-7): MG Thomas, J Zippin, and BP Brooks. Oculocutaneous albinism and ocular albinism overview. Unknown journal, 2023.
-
(galli2023oculocutaneousalbinismthe pages 4-5): Jessica Galli, Erika Loi, Laura Dusi, Nadia Pasini, Andrea Rossi, Vera Scaglioni, Lucia Mauri, and Elisa Fazzi. Oculocutaneous albinism: the neurological, behavioral, and neuro-ophthalmological perspective. European Journal of Pediatrics, 182:2723-2733, Apr 2023. URL: https://doi.org/10.1007/s00431-023-04938-w, doi:10.1007/s00431-023-04938-w. This article has 14 citations and is from a peer-reviewed journal.
